AlphaMark Advisors LLC Sells 650 Shares of Pfizer Inc. (NYSE:PFE)

AlphaMark Advisors LLC lowered its holdings in Pfizer Inc. (NYSE:PFE) by 38.2% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,053 shares of the biopharmaceutical company’s stock after selling 650 shares during the period. AlphaMark Advisors LLC’s holdings in Pfizer were worth $29,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in PFE. Advisor OS LLC increased its stake in Pfizer by 1.0% during the 4th quarter. Advisor OS LLC now owns 35,202 shares of the biopharmaceutical company’s stock worth $1,013,000 after acquiring an additional 365 shares during the period. Safeguard Investment Advisory Group LLC grew its holdings in shares of Pfizer by 3.9% during the 4th quarter. Safeguard Investment Advisory Group LLC now owns 9,987 shares of the biopharmaceutical company’s stock worth $288,000 after purchasing an additional 371 shares in the last quarter. Lantz Financial LLC increased its position in shares of Pfizer by 1.3% in the first quarter. Lantz Financial LLC now owns 30,582 shares of the biopharmaceutical company’s stock worth $849,000 after purchasing an additional 381 shares during the period. King Wealth Management Group raised its stake in Pfizer by 2.4% in the fourth quarter. King Wealth Management Group now owns 16,686 shares of the biopharmaceutical company’s stock valued at $480,000 after purchasing an additional 388 shares in the last quarter. Finally, Advance Capital Management Inc. lifted its position in Pfizer by 4.0% during the fourth quarter. Advance Capital Management Inc. now owns 10,177 shares of the biopharmaceutical company’s stock worth $293,000 after purchasing an additional 391 shares during the period. 68.36% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have commented on PFE shares. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Wednesday, June 26th. BMO Capital Markets restated an “outperform” rating and set a $36.00 target price (up from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Finally, Morgan Stanley lifted their price target on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday, May 2nd. Nine research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, Pfizer presently has a consensus rating of “Hold” and a consensus target price of $35.54.

Pfizer Price Performance

PFE stock traded up $0.24 during midday trading on Monday, reaching $28.22. 24,982,110 shares of the stock were exchanged, compared to its average volume of 40,791,203. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78. The stock has a market capitalization of $159.91 billion, a PE ratio of -470.25, a P/E/G ratio of 1.10 and a beta of 0.69. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $37.80. The company has a fifty day moving average price of $27.90 and a 200 day moving average price of $27.69.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The company had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. During the same quarter in the prior year, the firm posted $1.23 earnings per share. The firm’s revenue was down 19.5% compared to the same quarter last year. As a group, analysts expect that Pfizer Inc. will post 2.38 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be issued a dividend of $0.42 per share. The ex-dividend date is Thursday, July 25th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.95%. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.